Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Alveolus Bio logo — Harnessing the power of the live biotherapeutics and small m...

Alveolus Bio

Harnessing the power of the live biotherapeutics and small molecules for the prevention and treatment of lung diseases

Founded 2020 United States Boston, United States 9 employees Grant Total: $7.00M Biotechnology

General Information

Company Name Alveolus Bio
Founded Year 2020
Location United States Boston, United States
Employees 9
Industries Biotechnology
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Alveolus Bio. To contact Alveolus Bio, visit alveolusbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Alveolus Bio compare?

A PDF of Alveolus Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Alveolus Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Alveolus Bio

Alveolus Bio is a biotechnology startup, founded in 2020, with a mission to harness the power of live biotherapeutics and small molecules for the prevention and treatment of lung diseases. The company's pipeline includes preclinical stage live biotherapeutics for Idiopathic Pulmonary Fibrosis (IPF), Chronic Obstructive Pulmonary Disease (COPD), and Non-Cystic Fibrosis Bronchiectasis (NCFBE). Notably, their inhaled delivery method effectively targets the distal regions of the lungs, bypassing first-pass metabolism and enhancing efficacy while reducing adverse effects, setting their drugs apart from other treatments. Recently, they received a grant investment from Innovate Alabama on 09 August 2023. With a team comprising scientists, physicians, and innovators, Alveolus Bio is at the forefront of pioneering FDA-approved therapeutics for lung diseases.

Business keywords: Biotherapeutics, Lung diseases, Idiopathic Pulmonary Fibrosis (IPF), Chronic Obstructive Pulmonary Disease (COPD), Non-Cystic Fibrosis Bronchiectasis (NCFBE), Preclinical stage, Inhaled delivery, FDA-approved therapeutics, Small molecules, Live biotherapeutics, Distal lung targeting, Drug development, Innovation, Medical research, Efficacy

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Grant Undisclosed 1
Innovate Alabama
Innovate Alabama
09 Aug 2023
Grant $2.50M 1
National Heart, Lung and Blood Institute
National Heart, Lung and Blood Institute
15 Feb 2023
Seed Round $4.50M -
26 Oct 2021

Alveolus Bio Alternatives & Competitors

View All Alternatives
Alveolus Bio vs
SolAeroMed Inc.
SolAeroMed Inc.

Visit the post for more.

Seed
3 employees
Biotechnology, Health and Wellness
Alveolus Bio vs
Microbion Corporation
Microbion Corporation United States

Developing a disruptive new class of therapeutic drugs for the treatment of rare, chronic, and serio...

Venture round
16 employees
Biotechnology, Health Care
Alveolus Bio vs
AnnJi Pharmaceutical Co., Ltd.
AnnJi Pharmaceutical Co., Ltd. Taiwan

Taiwan's Leading New Drug Developer In Dermatology & Neurology

18 employees
Biotechnology, Health Care
View all alternatives

FAQ About Alveolus Bio

Harnessing the power of the live biotherapeutics and small molecules for the prevention and treatment of lung diseases
Alveolus Bio was founded in 2020.
Alveolus Bio is headquartered in Boston, United States.
Alveolus Bio operates in Biotechnology. Its work centres on Biotherapeutics, Lung diseases, Idiopathic Pulmonary Fibrosis (IPF) and Chronic Obstructive Pulmonary Disease (COPD).
Alveolus Bio has approximately 9 employees.
Alveolus Bio has completed 3 funding rounds, raising a total of $7.00M. The latest funding stage is Grant.
Top alternatives and competitors to Alveolus Bio include SolAeroMed Inc., Microbion Corporation, AnnJi Pharmaceutical Co., Ltd., Savara Inc., Orbit Discovery. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Alveolus Bio and SolAeroMed Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Alveolus Bio, https://bouncewatch.com/company/alveolus-bio, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout